Pfizer Inc. (NYSE:PFE) Stock Position Reduced by Fidelis Capital Partners LLC

Fidelis Capital Partners LLC cut its position in shares of Pfizer Inc. (NYSE:PFE) by 2.0% during the 4th quarter, HoldingsChannel.com reports. The firm owned 19,480 shares of the biopharmaceutical company’s stock after selling 404 shares during the period. Fidelis Capital Partners LLC’s holdings in Pfizer were worth $561,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also modified their holdings of the company. Xponance Inc. boosted its stake in Pfizer by 11.5% in the fourth quarter. Xponance Inc. now owns 891,024 shares of the biopharmaceutical company’s stock valued at $25,653,000 after acquiring an additional 91,843 shares during the period. Integral Investment Advisors Inc. increased its position in Pfizer by 15.7% in the fourth quarter. Integral Investment Advisors Inc. now owns 19,513 shares of the biopharmaceutical company’s stock worth $562,000 after buying an additional 2,649 shares during the period. Investors Asset Management of Georgia Inc. GA ADV increased its position in Pfizer by 1.9% in the fourth quarter. Investors Asset Management of Georgia Inc. GA ADV now owns 64,890 shares of the biopharmaceutical company’s stock worth $1,884,000 after buying an additional 1,217 shares during the period. Wright Investors Service Inc. grew its position in shares of Pfizer by 6.5% during the fourth quarter. Wright Investors Service Inc. now owns 50,949 shares of the biopharmaceutical company’s stock worth $1,467,000 after acquiring an additional 3,127 shares during the last quarter. Finally, HF Advisory Group LLC lifted its position in Pfizer by 20.5% in the 4th quarter. HF Advisory Group LLC now owns 67,611 shares of the biopharmaceutical company’s stock valued at $1,947,000 after purchasing an additional 11,479 shares during the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Stock Up 0.7 %

Shares of PFE traded up $0.17 during trading hours on Friday, reaching $25.56. The company’s stock had a trading volume of 9,438,132 shares, compared to its average volume of 42,027,188. The firm has a market cap of $144.73 billion, a price-to-earnings ratio of 70.51, a P/E/G ratio of 1.15 and a beta of 0.61. The company has a 50 day moving average of $27.14 and a two-hundred day moving average of $28.74. Pfizer Inc. has a 1-year low of $25.23 and a 1-year high of $40.37. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. The business had revenue of $14.25 billion for the quarter, compared to the consensus estimate of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. Pfizer’s revenue for the quarter was down 41.3% on a year-over-year basis. During the same quarter last year, the firm earned $1.14 EPS. As a group, research analysts predict that Pfizer Inc. will post 2.24 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have commented on PFE shares. TD Cowen cut shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price for the company. in a research report on Thursday, January 4th. Guggenheim started coverage on Pfizer in a research note on Friday, February 23rd. They set a “buy” rating and a $36.00 target price on the stock. Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research report on Monday. Twelve research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $36.88.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.